ABSTRACT
BACKGROUND: While data from USA and Canada demonstrate an opioid overdose epidemic, very little nation-wide European studies have been published on this topical subject. METHODS: Using a nationally representative sample of the French Claims database (>700,000 patients), the exhaustive nationwide hospital discharge database, and national mortality registry, all patients dispensed at least one prescription opioid (PO) in 2004-2017 were identified, to describe trends in PO analgesic use, shopping behaviour, opioid-related hospitalizations and deaths. Annual prevalence of PO use and shopping behaviour (≥1 day of overlapping prescriptions from ≥2 prescribers, dispensed by ≥3 pharmacies) was estimated. RESULTS: In 2004-2017, the annual prevalence of weak opioid use codeine, tramadol and opium rose by 150%, 123%, and 244%, respectively (p < 0.05). Strong opioid use increased from 0.54% to 1.1% (+104%, p < 0.05), significantly for oxycodone (+1950%). Strong opioid use in chronic noncancer pain rose by 88% (p < 0.05) and 1180% for oxycodone. Opioid shopping increased from 0.50% to 0.67% (+34%, p < 0.05), associated with higher mortality risk HR = 2.8 [95% confidence interval (CI): 1.2-6.4]. Opioid-related hospitalizations increased from 15 to 40 per 1,000,000 population (+167%, 2000-2017), and opioid-related deaths from 1.3 to 3.2 per 1,000,000 population (+146%, 2000-2015). CONCLUSIONS: This study provided a first European approach to a nationwide estimation with complete access to several national registries. In 2004-2017 in France, PO use excluding dextropropoxyphene more than doubled. The increase in oxycodone and fentanyl use, and nontrivial increasing trend in opioid-related morbidity-mortality should prompt authorities to closely monitor PO consumption in order to prevent alarming increases in opioid-related morbidity-mortality. SIGNIFICANCE: In 2004-2017, prescription opioid use in France at least doubled and oxycodone use increased particularly, associated with a nontrivial increase in opioid-related morbidity-mortality. Although giving no indication for an 'opioid epidemic,' these findings call for proper monitoring of opioid use.
Subject(s)
Analgesics, Opioid/therapeutic use , Chronic Pain/drug therapy , Mortality , Opioid-Related Disorders/epidemiology , Adult , Aged , Codeine/therapeutic use , Databases, Factual , Dextropropoxyphene/therapeutic use , Female , Fentanyl/therapeutic use , France/epidemiology , Humans , Male , Middle Aged , Opium/therapeutic use , Oxycodone/therapeutic use , Prevalence , Proportional Hazards Models , Tramadol/therapeutic useABSTRACT
Methotrexate is a folic acid analog, which is a thymidylate synthetase and dihydrofolate reductase inhibitor. It is used in oncology, dermatology and rheumatology and off labelling in the treatment of ectopic pregnancies. This paper is a review of methotrexate pharmacology with focus on data concerning ectopic pregnancies.
Subject(s)
Abortifacient Agents, Nonsteroidal/pharmacology , Methotrexate/pharmacology , Pregnancy, Ectopic/drug therapy , Female , Humans , PregnancyABSTRACT
BACKGROUND: In October 2009, in the context of an A(H1N1)v2009 influenza pandemic, a vaccination campaign was launched in France, in which one of the priority groups was pregnant women, on account of the high risk of developing complications following infection by this virus. OBJECTIVE: The aim of this multicentric, prospective, observational study was to assess safety and pregnancy outcomes in a cohort of pregnant women when receiving the A(H1N1)v2009 influenza pandemic vaccine. METHODS: This was a prospective study that followed up pregnant women recruited mainly in vaccination centres and maternity departments. Following the expected delivery date, follow-up data were collected concerning the delivery, the infant, and, if appropriate, the reasons why the pregnancy did not reach its term. RESULTS: Between 1 November 2009 and 31 March 2010, 2,415 pregnant women were included at the time of vaccination; 97.6 % of women received a vaccine without adjuvant and 2.4 % received an adjuvanted vaccine. Ninety-two (3.9 %) women were vaccinated during the first trimester of pregnancy, 1,090 (46.5 %) during the second trimester, and 1,162 (49.6 %) during the third trimester. One hundred and thirty-three adverse events (5.5 % of women) were reported, of which 12 were unexpected or serious. There were 2,246 (93.0 %) known pregnancy outcomes with 12 spontaneous abortions (0.5 %), 6 stillbirths (0.3 %), and 4 therapeutic abortions (0.2 %). There were 65 neonates with congenital anomalies, among which 31 were major. But only one congenital malformation (1.4 %) was reported for the 92 women vaccinated in their first trimester. Of the women, 93.3 % were delivered full term and 6.7 % preterm. For 96 (4.2 %) neonates, a disorder was reported in the neonatal period and 130 (5.6 %) were transferred to the neonatology department. CONCLUSIONS: This study suggests that exposure to the A(H1N1)v2009 pandemic influenza vaccine during pregnancy does not increase the risk of adverse pregnancy outcomes. However, because of the relatively small number of women exposed during the first trimester, other studies are needed to exclude an increased risk of malformation.
Subject(s)
Congenital Abnormalities/etiology , Influenza A Virus, H1N1 Subtype/immunology , Influenza Vaccines/adverse effects , Pregnancy Complications/etiology , Adolescent , Adult , Cohort Studies , Congenital Abnormalities/epidemiology , Female , Follow-Up Studies , France/epidemiology , Humans , Infant, Newborn , Influenza Vaccines/therapeutic use , Influenza, Human/immunology , Influenza, Human/prevention & control , Male , Middle Aged , Pregnancy , Pregnancy Complications/epidemiology , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/prevention & control , Pregnancy Outcome , Prospective Studies , Risk , Young AdultABSTRACT
OBJECTIVES: The aim of this study was to evaluate the incidence of paracetamol-induced hypotension in intensive care unit (ICU). The secondary end-point was the description of pathophysiologic phenomenon during this hypotension and risk factors. STUDY DESIGN: An observational study in three ICU of a French teaching hospital. PATIENTS AND METHODS: All consecutives patients whom benefit from intravenous paracetamol administration were included in the study. When a 20% droop in arterial blood pressure occurred, plasma samples were obtained and tryptases were measured at 6 and 48 hours. Clinical, biological characteristics and paracetamol administration duration were prospectively monitored. RESULTS: During a 2-months period, 127 ICU patients were included in the study with 1507 paracetamol administration. Twenty droops in arterial blood pressure were recorded in ICU. The incidence rate was 1.33%. Administration duration was 32+/-9 min. No respiratory nor cutaneous manifestations occurred during hypotensions. A specific treatment was administrated in half of the patients. Hypotension incidence was higher (3.9%) in patients with brain injury. Eighty percent of patients with hypotension have a severe sepsis or a septic shock. CONCLUSION: In this cohort of ICU patients, hypotension incidence was higher than reported in drug legal mentions. Immunoallergic phenomenon was excluded. Brain injury and sepsis seems to be risk factors.
Subject(s)
Acetaminophen/adverse effects , Analgesics, Non-Narcotic/adverse effects , Hypotension/chemically induced , Acetaminophen/administration & dosage , Aged , Analgesics, Non-Narcotic/administration & dosage , Blood Pressure/drug effects , Brain Injuries/complications , Brain Injuries/physiopathology , Endpoint Determination , Female , Hospitals, Teaching , Humans , Hypotension/epidemiology , Injections, Intravenous , Intensive Care Units , Male , Middle Aged , Prospective Studies , Risk Factors , Sepsis/complications , Sepsis/physiopathology , Shock, Septic/complications , Shock, Septic/physiopathologyABSTRACT
PURPOSE: Vein thrombosis risk and pulmonary embolism seem to be more important among human immunodeficiency virus (HIV) infected patients. METHOD: We performed a retrospective study including 780 HIV positive patients followed-up between January 2000 and June 2005 at the University Hospital of Clermont-Ferrand. RESULTS: Among the 780 HIV-infected patients, six cases of thromboembolic events were identified including, four with pulmonary embolism. All the patients were receiving lopinavir/ritonavir combination. CONCLUSION: Although uncommon, pulmonary embolism occurs more frequently among HIV positive patients than in general population. Clinicians must remain aware about the possibility of the occurrence of a thromboembolic event especially during the first few months after introduction of the antiretroviral therapy.
Subject(s)
Antiretroviral Therapy, Highly Active/statistics & numerical data , Pulmonary Embolism/epidemiology , Venous Thrombosis/epidemiology , Adult , Anti-HIV Agents/therapeutic use , Cohort Studies , Female , Follow-Up Studies , France/epidemiology , HIV Protease Inhibitors/therapeutic use , HIV Seropositivity/epidemiology , Humans , Lopinavir , Male , Middle Aged , Pyrimidinones/therapeutic use , Retrospective Studies , Ritonavir/therapeutic useABSTRACT
OBJECTIVES AND METHODS: To describe cases of fusidic acid-associated sideroblastic anaemia from the French Pharmacovigilance database. RESULTS: Six cases of sideroblastic anaemia associated with oral fusidic acid treatment were retrieved. Four females and two males (mean age 65.3 yr) developed severe anaemia (mean haemoglobin level: 6.9 g/dL) within 32-190 d (mean: 81 d) of treatment. Bone marrow aspirates showed dyserythropoiesis and ringed sideroblasts in all patients. Four patients required repeated blood transfusions. After fusidic acid discontinuation in five patients, complete recovery was obtained. In one patient, rechallenge with fusidic acid resulted in recurrence of anaemia that resolved after definitive discontinuation of the drug. CONCLUSION: Our data indicate that fusidic acid should be added to the list of drugs that can cause sideroblastic anaemia.
Subject(s)
Anemia, Sideroblastic/chemically induced , Fusidic Acid/adverse effects , Aged , Anemia, Sideroblastic/therapy , Bacterial Infections/drug therapy , Blood Transfusion , Drug Therapy, Combination/therapeutic use , Female , Humans , Hyperbilirubinemia/chemically induced , Male , Middle Aged , Neutropenia/chemically induced , Peripheral Nervous System Diseases/chemically induced , Pristinamycin/administration & dosage , Pristinamycin/adverse effects , Recurrence , Thrombocytopenia/chemically inducedSubject(s)
Anti-Anxiety Agents/adverse effects , Anti-Ulcer Agents/adverse effects , Confusion/chemically induced , Confusion/psychology , Enzyme Inhibitors/adverse effects , Proton Pump Inhibitors , 2-Pyridinylmethylsulfinylbenzimidazoles , Adult , Bromazepam/adverse effects , Humans , Lansoprazole , Male , Middle Aged , Omeprazole/adverse effects , Omeprazole/analogs & derivativesABSTRACT
In 1978, a systematic collection of adverse drug reactions (ADRs) was set up in a hospital including several departments and continued for more than 18 years. Quarterly meetings were organized gathering clinicians, students, nurses and pharmacologists to discuss the clinical cases collected each quarter. Approximately 100 cases were analysed each year (1823 over the 18-year period). Educational interest resulted from (1) discussion about some ADRs frequently leading to hospitalization or consultation; (2) information about recent drugs and new and/or not well known ADRs; (3) education of physicians for a good prescription of drugs and increasing awareness of pharmacovigilance.
Subject(s)
Acute Kidney Injury/chemically induced , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Hepatic Encephalopathy/chemically induced , Ketoprofen/adverse effects , Pancreatitis/chemically induced , Acute Disease , Acute Kidney Injury/diagnosis , Aged , Biopsy , Chemical and Drug Induced Liver Injury/diagnosis , Hepatic Encephalopathy/diagnosis , Humans , Liver Function Tests , Male , Pancreatitis/diagnosisABSTRACT
A similar pattern of psychosexual disorders has been observed after long-term treatment with levodopa therapy in four male parkinsonian patients treated with apomorphine for severe on-off motor fluctuations. An acute episode in each case had led them to the hospital in the context of a psychiatric emergency (after punishable sexual acts in two cases). In each case, this episode had been preceded by an increase of self-administered apomorphine, whereas other antiparkinsonian drugs remained unchanged. Questioning had revealed psychosexual disturbances as early as the onset of apomorphine treatment, which tended to progressively worsen with the number of apomorphine daily doses. A decrease in the dosage of apomorphine had been followed by the improvement of the psychiatric condition without worsening of the motor status. Recurrence of psychiatric disorders with similar features had been observed when two patients again increased the number of apomorphine daily injections. The absence of somatic manifestations when apomorphine treatment was withdrawn or reduced, with persistence of psychosexual disturbances, could suggest a psychological dependence from the drug.
Subject(s)
Antiparkinson Agents/adverse effects , Apomorphine/adverse effects , Dopamine Agonists/adverse effects , Parkinson Disease/drug therapy , Sexual Dysfunctions, Psychological/chemically induced , Aged , Antiparkinson Agents/administration & dosage , Apomorphine/administration & dosage , Dopamine Agonists/administration & dosage , Drug Overdose , Humans , Male , Middle Aged , Self AdministrationABSTRACT
UNLABELLED: The aim of this prospective epidemiological study was to investigate the incidence of Inflammatory Bowel Disease in the Puy-de-Dôme county using the same methodology as EPIMAD's registry. METHODS: From 01/01/93 to 31/12/94, each gastroenterologist (n = 22) collected patients consulting for the first time with clinical symptoms compatible with inflammatory bowel disease. Data were reported on a questionnaire by an interviewer practitioner. The final diagnosis of Crohn's disease and ulcerative colitis was made in a blind manner by two expert gastroenterologists and recorded according to the Calkin's criteria as definite, probable, or possible diagnosis, or unclassifiable chronic colitis or acute colitis. RESULTS: 167 new cases were identified: 112 (67.1%) inflammatory bowel disease for the combined group of definite and probable cases with 79 Crohn's disease (70.5%), 29 ulcerative colitis (25.9%) of which 11 ulcerative proctitis (37.9%), 4 unclassifiable chronic colitis (3.6%) and 55 acute colitis (32.9%). The crude and age-adjusted incidence (per 10(5)/year) was respectively 6.6 and 5.7 for Crohn's disease and 2.4 and 1.9 for ulcerative colitis. The highest age-specific incidence rate for Crohn's disease was between 40-49 years (14.1) and for ulcerative colitis between 80-89 years (6.8). The female/male ratio was 0.8 for Crohn's disease and 1.1 for ulcerative colitis. The median age at the time of diagnosis was 42.6 years for Crohn's disease and 35.3 years for ulcerative colitis. CONCLUSIONS: These preliminary findings revealed a high incidence of Crohn's disease and low of ulcerative colitis in this county. However, these results must be managed carefully because these data were recorded only on two years and the inflammatory bowel disease classified possible and acute colitis require a follow-up.